Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review

Détails

ID Serval
serval:BIB_BD02DE37717F
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Titre
Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review
Périodique
Dermatology
Auteur(s)
Juillerat  P., Christen-Zach  S., Troillet  F. X., Gallot-Lavallee  S., Pannizzon  R. G., Michetti  P.
ISSN
1421-9832 (Electronic)
Statut éditorial
Publié
Date de publication
2007
Volume
215
Numéro
3
Pages
245-51
Notes
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Review
Résumé
We report the case of a 19-year-old woman who developed an acute disseminated pyoderma gangrenosum (PG) during a severe flare of ulcerative colitis (UC). She was successfully treated with a 3-dose regimen of the anti-tumor-necrosis-factor-alpha antibody infliximab. The literature on the effectiveness of this biological agent was reviewed, including 8 other cases of UC-associated PG and 77 cases of Crohn's-disease-associated PG. This case report and the review of the literature demonstrate that infliximab can be successfully used to treat patients with PG associated with inflammatory bowel diseases.
Mots-clé
Adult Antibodies, Monoclonal/*therapeutic use Colitis, Ulcerative/*complications Dermatologic Agents/*therapeutic use Female Humans Pyoderma Gangrenosum/*drug therapy/etiology
Pubmed
Web of science
Création de la notice
25/01/2008 17:01
Dernière modification de la notice
03/03/2018 20:58
Données d'usage